...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Urology >Quality of life and functional outcome after infravesical desobstruction and HIFU treatment for localized prostate cancer
【24h】

Quality of life and functional outcome after infravesical desobstruction and HIFU treatment for localized prostate cancer

机译：局灶性通肠梗阻和HIFU治疗局部前列腺癌后的生活质量和功能结局

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background To evaluate quality of life, functional and oncological outcome after infravesical desobstruction and HIFU treatment for localized prostate cancer. Methods One hundred thirty-one patients, treated with TURP and HIFU in a single institution were followed up for oncological and functional outcome. Oncological outcome was quantified by biochemical recurrence free survival using the Stuttgart and Phoenix criteria. Quality of life was assessed by usage of standardized QLQ-C30 and QLQ-PR25 questionnaires. In addition, functional questionnaires such as IPSS and IIEF-5 were used. Complications were assessed by the Clavien-Dindo classification. Results One hundred thirty-one patients with a mean age of 72.8?years (SD: 6.0) underwent HIFU for prostate cancer (29.0% low risk, 58.8% intermediate risk, 12.2% high risk). PSA nadir was 0.6?ng/ml (SD: 1.2) after a mean of 4.6?months (SD: 5.7). Biochemical recurrence free survival defined by Stuttgart criteria was 73.7%, 84.4% and 62.5% for low-, intermediate- and high-risk patients after 22.2?months. Complications were grouped according to Clavien-Dindo and occurred in 10.7% (grade II) and 11.5% (grade IIIa) of cases. 35.1% of patients needed further treatment for bladder neck stricture. Regarding incontinence, 14.3%, 2.9% and 0% of patients had de novo urinary incontinence grade I°, II° and III° and 3.8% urge incontinence due to HIFU treatment. Patients were asked for the ability to have intercourse: 15.8%, 58.6% and 66.7% of patients after non-, onesided and bothsided nervesparing procedure were able to obtain sufficient erection for intercourse, respectively. Regarding quality of life, mean global health score according to QLQ-C30 was 69.4%. Conclusion HIFU treatment for localized prostate cancer shows acceptable oncological safety. Quality of life after HIFU is better than in the general population and ranges within those of standard treatment options compared to literature. HIFU seems a safe valuable treatment alternative for patients not suitable for standard treatment.
机译：背景技术为评估局灶性前列腺癌的膀胱腔内通畅和HIFU治疗后的生活质量，功能和肿瘤学结局。方法对单机构接受TURP和HIFU治疗的113例患者进行肿瘤和功能预后随访。肿瘤学结果通过斯图加特和菲尼克斯标准通过无生化复发的生存率进行定量。生活质量通过使用标准化QLQ-C30和QLQ-PR25问卷进行评估。此外，还使用了IPSS和IIEF-5等功能问卷。并发症通过Clavien-Dindo分类进行评估。结果131例平均年龄为72.8岁（标准差：6.0）的患者接受了HIFU治疗前列腺癌（低风险29.0％，中风险58.8％，高风险12.2％）。在平均4.6个月（SD：5.7）之后，PSA最低点为0.6ng / ml（SD：1.2）。在22.2个月后，低，中和高风险患者的斯图加特标准所定义的无生化复发的生存率分别为73.7％，84.4％和62.5％。根据Clavien-Dindo将并发症分组，分别在10.7％（II级）和11.5％（IIIa级）的病例中发生。 35.1％的患者需要进一步治疗以治疗膀胱颈狭窄。关于尿失禁，由于HIFU治疗，新发尿失禁I°，II°和III°的患者分别为14.3％，2.9％和0％，急迫性尿失禁为3.8％。要求患者具有性交能力：非保留，单侧和双侧神经保留手术后分别有15.8％，58.6％和66.7％的患者能够获得足够的勃起进行性交。关于生活质量，根据QLQ-C30得出的全球平均健康评分为69.4％。结论HIFU治疗局限性前列腺癌具有良好的肿瘤学安全性。 HIFU后的生活质量优于一般人群，与文献相比，在标准治疗方案的范围内。对于不适合标准治疗的患者，HIFU似乎是安全，有价值的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号